Clinical impacts of immunomodulator withdrawal from anti‐tumor necrosis factor combination therapy in pediatric inflammatory bowel disease
Immunomodulator withdrawal was not associated with worsening of disease activity in patients with Crohn’s disease or ulcerative colitis.